Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Riociguat (Adempas®) is recommended for use within NHS Wales for the treatment of adult patients with WHO functional class II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH); or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. |
|||
|
|||
Medicine details |
|||
| Medicine name | riociguat (Adempas®) | ||
| Formulation | 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg film-coated tablet | ||
| Reference number | 1608 | ||
| Indication | Treatment of adult patients with WHO functional class II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH); or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity |
||
| Company | Merck Sharp & Dohme Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 2415 | ||
| NMG meeting date | 22/07/2015 | ||
| AWMSG meeting date | 16/09/2015 | ||
| Ratification by Welsh Government | 09/10/2015 | ||
| Date of issue | 13/10/2015 | ||
| Date of last review | 25/03/2019 | ||
| Commercial arrangement | WPAS | ||